Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
BACKGROUND The mechanism underlying rapid , statin-induced event reduction in patients with an acute coronary syndrome ( ACS ) remains to be clarified . AIM The primary objective is to compare the efficacy of rosuvastatin 20 mg/day and atorvastatin 80 mg/day in reducing the apolipoprotein B/apolipoprotein A-1 ( apoB/apoA-1 ) ratio at three months , in ACS patients . Secondary objectives include a comparison of the effects of early-started rosuvastatin and placebo on inflammatory markers . METHODS This is a r and omized , double-blind , parallel-group study . Patients with non-ST-segment elevation ACS , symptom onset less than 48 h before admission , and for whom a percutaneous coronary intervention is planned , are eligible for inclusion and are r and omized into three groups ( G1 , G2 and G3 ) . The study comprises two double-blind periods . Period 1 starts at hospital admission and lasts until Day 0 ( discharge or less or equal to 6 days after admission ) ; patients in G1 receive one tablet of rosuvastatin 20 mg/day and patients in G2 and G3 receive one matching placebo tablet per day . Period 2 starts at Day 0 and lasts for three months ; patients in G1 continue to receive rosuvastatin 20 mg/day , patients in G2 receive rosuvastatin 20 mg/day and patients in G3 receive atorvastatin 80 mg/day . Recruitment of 1075 patients will ensure an 80 power to detect a 3 % difference in percentage change in the apoB/apoA-1 ratio and a 20 % difference in percentage change in high-sensitivity C-reactive protein . RESULTS Inclusion phase is complete ; results will be reported at a later date . CONCLUSION This is the first trial investigating the effect of statins on apolipoproteins in ACS patients
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .